We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

269 hedge funds and large institutions have $6.9B invested in Iovance Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 86 increasing their positions, 97 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $120M | Put options by funds: $77.8M

51% more capital invested

Capital invested by funds: $4.58B → $6.9B (+$2.32B)

46% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 39

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

7% more funds holding

Funds holding: 252 → 269 (+17)

5.83% more ownership

Funds ownership: 95.58% → 101.41% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 97

Holders
269
Holders Change
+17
Holders Change %
+6.75%
% of All Funds
4.76%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
57
Increased
86
Reduced
97
Closed
39
Calls
$120M
Puts
$77.8M
Net Calls
+$42M
Net Calls Change
+$15.8M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$294M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
3
CCM
Consonance Capital Management
New York
+$67.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$53.1M
5
NAMA
Nikko Asset Management Americas
New York
+$35.9M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$117M
2
ACA
Avoro Capital Advisors
New York
-$80.8M
3
PA
Perceptive Advisors
New York
-$36.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
76
Two Sigma Advisers
New York
$5.76M +$3.13M +78,900 +175%
CM
77
Castleark Management
Illinois
$5.06M +$4.33M +109,000 New
E
78
Ergoteles
New York
$4.81M +$1.6M +40,317 +64%
Jane Street
79
Jane Street
New York
$4.79M -$2.79M -70,371 -41%
DP
80
DSAM Partners
United Kingdom
$4.74M +$4.06M +102,157 New
MAP
81
Moody Aldrich Partners
Massachusetts
$4.69M +$1.41M +35,454 +54%
6CM
82
683 Capital Management
New York
$4.64M – – –
TRSOTSOK
83
Teachers Retirement System of the State of Kentucky
Kentucky
$4.58M +$3.92M +98,747 New
TAM
84
Tocqueville Asset Management
New York
$4.43M +$2.4M +60,450 +173%
Legal & General Group
85
Legal & General Group
United Kingdom
$4.33M -$738K -18,584 -17%
UBS Group
86
UBS Group
Switzerland
$3.97M +$542K +13,650 +19%
HF
87
HRT Financial
New York
$3.76M +$3.21M +80,965 New
CIA
88
Capital Impact Advisors
Massachusetts
$3.71M – – –
SFI
89
Susquehanna Fundamental Investments
Pennsylvania
$3.57M – – –
Susquehanna International Group
90
Susquehanna International Group
Pennsylvania
$3.38M -$27.1M -682,028 -90%
Wells Fargo
91
Wells Fargo
California
$3.35M -$1.77M -44,567 -38%
State of New Jersey Common Pension Fund D
92
State of New Jersey Common Pension Fund D
New Jersey
$3.32M -$241K -6,074 -8%
GC
93
Guggenheim Capital
Illinois
$3.22M -$526K -13,243 -16%
AI
94
ArchPoint Investors
Florida
$3.21M +$2.28M +57,418 +489%
Ohio Public Employees Retirement System (OPERS)
95
Ohio Public Employees Retirement System (OPERS)
Ohio
$3.14M +$517K +13,027 +24%
Barclays
96
Barclays
United Kingdom
$3.09M +$302K +7,617 +13%
DekaBank Deutsche Girozentrale
97
DekaBank Deutsche Girozentrale
Germany
$3.05M +$1.42M +35,800 +129%
EAM
98
Erste Asset Management
Austria
$3.05M +$834K +21,000 +49%
Deutsche Bank
99
Deutsche Bank
Germany
$2.84M -$10K -252 -0.4%
IBT
100
International Biotechnology Trust
United Kingdom
$2.69M -$3.45M -87,000 -60%
2 3
4
5 6

IOVA Hedge Fund Activity: Q4 2020 in Review

269 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2020, worth a combined $6.9B — up 51% from $4.58B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new IOVA positions and 39 closed out — a net gain of 18 holders — while 86 added to existing stakes and 97 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $294M. The largest seller was Great Point Partners, cutting an estimated $117M.

  • 269 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2020, up from 252 in Q3 2020.
  • Funds reported $6.9B of Iovance Biotherapeutics stock for Q4 2020, up 51% quarter-over-quarter.
  • 57 funds opened new Iovance Biotherapeutics positions in Q4 2020 and 39 closed out, a net change of +18 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $294M added.
  • The largest Iovance Biotherapeutics seller in Q4 2020 was Great Point Partners, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.